[English]  [Pусский]  [中文]  
ctt-journal > Kulikova et al. (Abstract)

Kulikova et al. (Abstract)

Cellular Therapy and Transplantation (CTT), Vol. 3, No. 9
doi: 10.3205/ctt-2010-No9-abstract50
© The Authors. This abstract is provided under the following license: Creative Commons Attribution 3.0 Unported

Abstract accepted for "4th Raisa Gorbacheva Memorial Meeting on Hematopoietic Stem Cell Transplantation",
Saint Petersburg, Russia, September 18–20, 2010

Contribute a comment


The long-term outcome of BFM-based therapy for childhood lymphoblastic lymphoma in the Moscow region

Stanislava S. Kulikova1, Sergey V. Semochkin1, Dmitry V. Litvinov1,2, Eugenia V. Inyushkina1,3, Natalya V. Myakova1,2, Konstantin L. Kondratchkik1,4, Lyudmila V. Baydun1,2, Dmitry M. Konovalov1,4, Dmitry A. Peregudov1,3, Larisa N. Shelehova1,2, Elena V. Samochatova1

1Federal Scientific Clinical Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia; 2Russian Children's Clinical Hospital, Moscow, Russia; 3Regional Oncology Dispensary, Balashikha, Russia; 4Children's Clinical Hospital n.a. Morozov, Moscow, Russia

Correspondence: Stanislava S. Kulikova, Federal Scientific Clinical Center of Pediatric Hematology, Oncology and Immunology, 117/2, Leninsky pr., 117997, Moscow, Russia, E-mail: adolescent.hematology@spam is badgmail.com


Lymphoblastic lymphoma (LBL) is one of predominant childhood non-Hodgkin’s lymphoma (NHL) subtypes. However, excellent outcomes have been achieved with acute lymphoblastic leukemia (ALL)-type treatments in children with LBL.

The purpose of this study was to investigate outcomes children and adolescents with LBL treated with the NHL-BFM 90 and 95 protocols in the Moscow region.

Methods: 58 pts (m, - 40; f, - 18) were enrolled in this study from May 1991 to August 2008. Fifty-two (90%) pts were treated with the ALL-like therapy protocol NHL-BFM 90 or 95 for non-B-NHL (ALL-type) patients, and 6 (10%) –with NHL-BFM 90 for B-NHL. These protocols differed from the original by reduction of the methotrexate dose (1 g/m2/24h instead of 5 g/m2/24h).

Results: The median age at time of presentation was 11.0 (range 1.5–21.6) years. Forty-five (90%) pts have a T -cell immunophenotype. Fifty-three (91%) had advanced (III, IV) stage disease. The presenting sites of T-LBL included mediastinal mass and bone marrow in 35 (78%) and 13 (29%) cases respectively. CR was 94 and 83% for non-B-NHL and B-NHL treatment respectively. Five-year event free survival (5y-EFS) was 0.80 ± 0.06 (median of observation 4.1 years) and 0.67 ± 0.19 (5.1 years) respectively (p > 0.05). Five-year overall survival (5y-OS) was 0.85 ± 0.05 and 0.80 ± 0.06 respectively (p > 0.05). The situation without mediastinal involvement was a factor for an unfavorable prognosis for T-LBL: 5y-EFS –was 0.56 ± 0.17 vs. 0.90 ± 0.05 (p = 0.036). Sex, age, increased LDH, slow or fast therapy response, and involvement of the central nervous system or bone marrow did not affect the prognosis (p > 0.05).

Conclusions: The NHL-BFM 90 and 95 for non-B-NHL protocols are effective therapeutic regimes for pediatric LBL, and the long-term results obtained are comparable with international data.

Keywords: lymphoblastic lymphoma, non-Hodgkin’s lymphoma, children, adolescents, therapy, NHL-BFM 90/95


<-- Previous abstract        Contents        Next abstract -->

Contribute a comment